Skip to main content

Table 6 Results of phase II trials in esophageal cancer

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Author Regimen Histology Therapy line Response rate (%) TTP/PFS OS
Lee [20] XP (X:2,500 mg/m2 D1-14
CDDP:60 mg/m2; D1)
SCC
(n = 45)
1st line
(n = 45)
57.8% 4.7 mon 11.2 mon
Van Meerten [18] XELOX
(X:2,000 mg/m2 D1-14
O:130 mg/m2; D1)
ADC (n = 45)
SCC (n = 4)
Undiff. (n = 2)
1st line
(n = 51)
39% NR 8 mon
MB Polee [28] Paclitaxel:180 mg/m2;D1
CDDP:60 mg/m2; D1
ADC (n = 31)
SCC (n = 16)
Undiff (n = 4)
1st line
(n = 51)
ADC (39%)
SCC (44%)
NR 9 mon
Zhang [29] Paclitaxel:175 mg/m2 on D1
CDDP:75 mg/m2 (D1)
SCC
(n = 35)
1st line
(n = 35)
48.6% 7 mon 13 mon
S.Lorenzen [21] DX
(X:2,000 mg/m2 D1-14
D:75 mg/m2; D1)
ADC (n = 7)
SCC (n = 17)
1st (n = 16)
2nd (n = 8)
1st (56%)
2nd (25%)
Overall = 46%
6.1 mon 1st (15.8)
2nd (6.2)
S.Lorenzen [26] FP + Cetuximab vs
FP
SCC (n = 62) 1st line
(n = 62)
FP+ Cetuximab (19%)
FP (13%)
5.9 mon
3.6 mon
9.5 mon
5.5 mon
Current Study Xeloda 1,800 mg/m2 D1-14
Paclitaxel:80 mg/m2 on D1, D8
SCC (n = 32) 1st (n = 12)
2nd (n = 20)
1st (75%)
2nd (45%)
Overall = 53.6%
5.23 mon
4.54 mon
14.3 mon
8.4 mon
  1. Abbreviations: XP, capecitabine/cisplatin; XELOX, capecitabine/oxaliplatin; DX, docetaxel/capecitabine; FP, 5-fluorouracil/cisplatin; SCC, squamous cell carcinoma; ADC, adenocarcinoma; Undiff, undifferentiated carcinoma; TTP, time to progression; PFS, progression-free survival; OS, overall survival; NR, not reported.